GLP-1 agonists may represent a paradigm shift: metabolic drugs with measurable effects on craving and reward circuitry
Medical weight loss uses provider-guided treatment, lab review, nutrition support, lifestyle planning, and when appropriate, medication or peptide-based support to help patients lose weight safely
The GLP-1 maintenance dose guide explains how to find your minimum effective dose for weight maintenance
4 Moreover, Novo Nordisks recent SELECT trial demonstrated that Wegovy reduces the risk of cardiovascular events
In theory, targeting both pathways simultaneously could produce greater appetite suppression than either drug alone
This means it remains in various stages of clinical trials, and its long-term efficacy and safety profile for this indication are still under evaluation